LEE011 for Melanoma (LOGIC-2 Trial)

"Unfortunately, this research protocol has already stopped recruiting participants. It was initially posted on July 23rd 2014 and last updated December 4th 2022. Nevertheless, there are currently 757 clinical trials searching for melanoma patients and 134 active studies enrolling people taking LEE011."

"LEE011 was initially researched in 2011 by St. Luke's University Health Network, and subsequently there have been 131 successful trials conducted. The medication is currently being tested at 134 clinical sites around the world, with a significant proportion of these tests taking place within Toronto, Ontario."

"We rate LEE011's safety a 2, as this is phase two and there are data points affirming its security but no clinical trial results proving efficacy."

"LEE011 has proven to be a beneficial therapeutic for malignant neoplasms, as well as unresectable melanoma, postmenopause, and human Fgfr2 protein."

"Patients are being accepted from Princess Margaret Cancer Center in Toronto, Sir Mortimer B. Davis-Jewish General Hospital in Montreal, and OHSU Knight Cancer Institute in Portland, as well as other 20 sites across North America."

"This research is no longer seeking potential subjects. Initially posted on July 23rd 2014, and most recently updated on December 4th 2022, it has since been concluded. However, if you are exploring alternatives then 757 studies associated with melanoma and 134 trials using LEE011 are presently recruiting participants."

"Since 2011, the drug LEE011 has been studied extensively. Initially sponsored by Pfizer, this medication was first trialled in 2011 and after a successful 183-person study it received Phase 2 approval. Currently, there are 134 active studies concerning LEE011 taking place across 54 nations within 1608 cities worldwide."